Induction versus escalation therapy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Most of the consensus groups in Europe and America support an early decision-making therapeutic approach in patients with a diagnosis of multiple sclerosis (MS), either with interferon-β or glatiramer acetate, which have been demonstrated to be a reasonable therapeutic strategy because of their benefit. The "treat-early approach" within disease management is based on the assumption, particularly during the early phase of the disease, of the reduction of both relapse rate and of the ongoing inflammatory processes may delay irreversible neurological damages. As soon as the MS diagnosis is certain or even in patients with a first episode suggestive of MS, with negative prognostic factors and a typical presentation, "induction therapy", which is more aggressive on the immune system, seems to have more relevant short- and long-lasting beneficial effects. However, if the disease course is suboptimally controlled, an "escalating strategy", using mitoxantrone, cyclophosphamide, various other immunoactive agents or a combination of different drugs, is suggested. The current challenge in therapeutic strategy is to identify the most effective drug, or combination of drugs, during a specific phase of the disease for each single patient. Anyhow, the decision to adopt a combination therapy in patients with a low response to monotherapy should not be delayed until severe irreversible disability is evident.

Original languageEnglish
JournalNeurological Sciences
Volume26
Issue numberSUPPL. 4
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Multiple Sclerosis
Drug Combinations
Therapeutics
Mitoxantrone
Disease Management
Cyclophosphamide
Interferons
Immune System
Consensus
Decision Making
Recurrence
Pharmaceutical Preparations
Glatiramer Acetate

Keywords

  • Escalation therapy
  • Immunomodulatory agents
  • Immunosuppressive agents
  • Induction therapy
  • Magnetic resonance imaging
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Induction versus escalation therapy. / Martinelli, Vittorio; Comi, G.

In: Neurological Sciences, Vol. 26, No. SUPPL. 4, 12.2005.

Research output: Contribution to journalArticle

@article{4bce639f04e94f0d9862a1159f6e3cb3,
title = "Induction versus escalation therapy",
abstract = "Most of the consensus groups in Europe and America support an early decision-making therapeutic approach in patients with a diagnosis of multiple sclerosis (MS), either with interferon-β or glatiramer acetate, which have been demonstrated to be a reasonable therapeutic strategy because of their benefit. The {"}treat-early approach{"} within disease management is based on the assumption, particularly during the early phase of the disease, of the reduction of both relapse rate and of the ongoing inflammatory processes may delay irreversible neurological damages. As soon as the MS diagnosis is certain or even in patients with a first episode suggestive of MS, with negative prognostic factors and a typical presentation, {"}induction therapy{"}, which is more aggressive on the immune system, seems to have more relevant short- and long-lasting beneficial effects. However, if the disease course is suboptimally controlled, an {"}escalating strategy{"}, using mitoxantrone, cyclophosphamide, various other immunoactive agents or a combination of different drugs, is suggested. The current challenge in therapeutic strategy is to identify the most effective drug, or combination of drugs, during a specific phase of the disease for each single patient. Anyhow, the decision to adopt a combination therapy in patients with a low response to monotherapy should not be delayed until severe irreversible disability is evident.",
keywords = "Escalation therapy, Immunomodulatory agents, Immunosuppressive agents, Induction therapy, Magnetic resonance imaging, Multiple sclerosis",
author = "Vittorio Martinelli and G. Comi",
year = "2005",
month = "12",
doi = "10.1007/s10072-005-0519-1",
language = "English",
volume = "26",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Induction versus escalation therapy

AU - Martinelli, Vittorio

AU - Comi, G.

PY - 2005/12

Y1 - 2005/12

N2 - Most of the consensus groups in Europe and America support an early decision-making therapeutic approach in patients with a diagnosis of multiple sclerosis (MS), either with interferon-β or glatiramer acetate, which have been demonstrated to be a reasonable therapeutic strategy because of their benefit. The "treat-early approach" within disease management is based on the assumption, particularly during the early phase of the disease, of the reduction of both relapse rate and of the ongoing inflammatory processes may delay irreversible neurological damages. As soon as the MS diagnosis is certain or even in patients with a first episode suggestive of MS, with negative prognostic factors and a typical presentation, "induction therapy", which is more aggressive on the immune system, seems to have more relevant short- and long-lasting beneficial effects. However, if the disease course is suboptimally controlled, an "escalating strategy", using mitoxantrone, cyclophosphamide, various other immunoactive agents or a combination of different drugs, is suggested. The current challenge in therapeutic strategy is to identify the most effective drug, or combination of drugs, during a specific phase of the disease for each single patient. Anyhow, the decision to adopt a combination therapy in patients with a low response to monotherapy should not be delayed until severe irreversible disability is evident.

AB - Most of the consensus groups in Europe and America support an early decision-making therapeutic approach in patients with a diagnosis of multiple sclerosis (MS), either with interferon-β or glatiramer acetate, which have been demonstrated to be a reasonable therapeutic strategy because of their benefit. The "treat-early approach" within disease management is based on the assumption, particularly during the early phase of the disease, of the reduction of both relapse rate and of the ongoing inflammatory processes may delay irreversible neurological damages. As soon as the MS diagnosis is certain or even in patients with a first episode suggestive of MS, with negative prognostic factors and a typical presentation, "induction therapy", which is more aggressive on the immune system, seems to have more relevant short- and long-lasting beneficial effects. However, if the disease course is suboptimally controlled, an "escalating strategy", using mitoxantrone, cyclophosphamide, various other immunoactive agents or a combination of different drugs, is suggested. The current challenge in therapeutic strategy is to identify the most effective drug, or combination of drugs, during a specific phase of the disease for each single patient. Anyhow, the decision to adopt a combination therapy in patients with a low response to monotherapy should not be delayed until severe irreversible disability is evident.

KW - Escalation therapy

KW - Immunomodulatory agents

KW - Immunosuppressive agents

KW - Induction therapy

KW - Magnetic resonance imaging

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=30644467098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30644467098&partnerID=8YFLogxK

U2 - 10.1007/s10072-005-0519-1

DO - 10.1007/s10072-005-0519-1

M3 - Article

C2 - 16388357

AN - SCOPUS:30644467098

VL - 26

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 4

ER -